Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
NCFB is a chronic lung condition where damaged airways cause persistent coughing and mucus production
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East
Nadda underlined that India’s policy framework is aligned with this transformation
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The program offers selected participants advanced access to Promise Bio’s broad-epiproteomic platform
This partnership represents a systemic shift from awareness to large-scale action for 57 lakh children
Under the deal, Quiver will receive an undisclosed advance payment and research support
Subscribe To Our Newsletter & Stay Updated
